

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

TT2609-C02

RRID:CVCL_2218

Type: Cell Line

Proper Citation

RRID:CVCL_2218

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2218

Proper Citation: RRID:CVCL_2218

Description: Cell line TT2609-C02 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Thyroid gland follicular carcinoma

Defining Citation: [PMID:11716037](#), [PMID:18713817](#), [PMID:22460905](#), [PMID:23833040](#), [PMID:25675381](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29066502](#), [PMID:30737244](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31443247](#), [PMID:35839778](#)

Comments: Karyotypic information: Near tetraploid karyotype (PubMed=11716037)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TT2609-C02

Synonyms: TT2609-CO2, TT2609C02

Cross References: CLO:CLO_0037156, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03473513, BioSample:SAMN10989561, cancercellines:CVCL_2218, Cell_Model_Passport:SIDM00418, Cosmic:1995660, Cosmic:2054095, Cosmic-CLP:1240223, DepMap:ACH-000716, DSMZ:ACC-510, DSMZCellDive:ACC-510, EGA:EGAS00001000978, GDSC:1240223, GEO:GSM887712, GEO:GSM888805, GEO:GSM1670550, IARC_TP53:28237, LiGeA:CCLE_442, LINCS_LDP:LCL-1681, Pharmacodb:TT2609C02_1607_2019, PRIDE:PXD030304,

Progenetix:CVCL_2218, Wikidata:Q54973225

ID: CVCL_2218

Record Creation Time: 20220427T221636+0000

Record Last Update: 20260905T182609+0000

Ratings and Alerts

No rating or validation information has been found for TT2609-C02.

No alerts have been found for TT2609-C02.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ablinger C, et al. (2026) Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer. International journal of cancer.

Marlow LA, et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. The Journal of clinical endocrinology and metabolism, 103(9), 3169.